Quest Partners LLC Acquires 9,096 Shares of Zymeworks Inc. (NYSE:ZYME)

Quest Partners LLC boosted its stake in shares of Zymeworks Inc. (NYSE:ZYME) by 8,049.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,209 shares of the company’s stock after acquiring an additional 9,096 shares during the quarter. Quest Partners LLC’s holdings in Zymeworks were worth $78,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its holdings in shares of Zymeworks by 2.9% in the 1st quarter. California State Teachers Retirement System now owns 43,420 shares of the company’s stock worth $457,000 after acquiring an additional 1,215 shares during the last quarter. Arizona State Retirement System raised its position in Zymeworks by 11.1% in the 2nd quarter. Arizona State Retirement System now owns 12,841 shares of the company’s stock worth $109,000 after purchasing an additional 1,285 shares during the period. ProShare Advisors LLC lifted its stake in Zymeworks by 11.1% in the first quarter. ProShare Advisors LLC now owns 14,952 shares of the company’s stock worth $157,000 after purchasing an additional 1,499 shares during the last quarter. SummerHaven Investment Management LLC lifted its stake in Zymeworks by 2.0% in the second quarter. SummerHaven Investment Management LLC now owns 90,158 shares of the company’s stock worth $767,000 after purchasing an additional 1,772 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Zymeworks by 17.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,664 shares of the company’s stock valued at $165,000 after buying an additional 2,351 shares during the period. 92.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZYME has been the subject of a number of research analyst reports. Stifel Nicolaus raised their price target on Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. HC Wainwright reiterated a “neutral” rating and set a $10.00 target price on shares of Zymeworks in a research report on Thursday, June 6th.

Zymeworks Stock Down 1.7 %

Shares of NYSE ZYME opened at $12.30 on Wednesday. Zymeworks Inc. has a twelve month low of $6.01 and a twelve month high of $13.14. The firm has a market cap of $873.92 million, a PE ratio of -6.87 and a beta of 1.19. The business has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $9.86.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The firm had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same period in the previous year, the company posted ($0.76) earnings per share. On average, research analysts expect that Zymeworks Inc. will post -0.85 earnings per share for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.